Risk of Hypertension with Regorafenib in Cancer Patients: a Systematic Review and Meta-analysis

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2013 Oct 24

PMID 24150533

Citations 25

Authors

Zexing Wang

Jing Xu

Weiwei Nie

Guichun Huang

Jinhai Tang

Xiaoxiang Guan

Affiliations

Soon will be listed here.

Abstract

Background: Regorafenib is a novel multikinase inhibitor approved for use in metastatic colorectal cancer (mCRC) and locally advanced gastrointestinal stromal tumors (GISTs). Hypertension is one of the major adverse events of this agent, but to date the incidence and risk of hypertension with regorafenib have not been systematically investigated. We have conducted a systematic review and meta-analysis of published clinical trials to determine its overall incidence and risk.

Methods: PubMed, Web of Science and abstracts presented at the American Society of Clinical Oncology annual meetings were searched to identify relevant studies published up to September 9, 2013. Eligible studies were prospective phase II or III clinical trials using regorafenib in cancer patients with data on hypertension available. The incidence and relative risk (RR) of hypertension were calculated using a random-effects model.

Results: Data from a total of 1,069 patients (regorafenib n = 750; controls n = 319) from five clinical trials were included for analysis. The overall incidence of all-grade and high-grade hypertension were 44.4 % [95 % confidence interval (CI) 30.8-59.0 %) and 12.5 % (95 % CI 5.2-27.1 %), respectively. The use of regorafenib in cancer patients was associated with a significantly increased risk of all-grade (RR 3.76, 95 % CI 2.35-5.99) and high-grade (RR, 8.39, 95 % CI 3.10-22.71) hypertension. The risk might vary with tumor types (P = 0.000).

Conclusions: Patients with cancer receiving regorafenib have a significantly higher risk of developing hypertension. Close monitoring and appropriate management of this hypertension are strongly recommended.

Citing Articles

Phenotypic screening in Organ-on-a-Chip systems: a 1537 kinase inhibitor library screen on a 3D angiogenesis assay.

Soragni C, Queiroz K, Ng C, Stok A, Olivier T, Tzagkaraki D Angiogenesis. 2023; 27(1):37-49.

PMID: 37493987 PMC: 10881651. DOI: 10.1007/s10456-023-09888-3.

Severe hypertension development significantly improves progression-free survival in regorafenib treatment for metastatic colorectal cancer.

Saito Y, Takekuma Y, Komatsu Y, Sugawara M Int J Clin Oncol. 2023; 28(9):1183-1190.

PMID: 37322220 DOI: 10.1007/s10147-023-02364-4.

Risk factor analysis for regorafenib-induced severe hypertension in metastatic colorectal cancer treatment.

Saito Y, Takekuma Y, Komatsu Y, Sugawara M Support Care Cancer. 2022; 30(12):10203-10211.

PMID: 36217043 DOI: 10.1007/s00520-022-07381-z.

Risks and management of hypertension in cancer patients undergoing targeted therapy: a review.

Zhu X, Wu S Clin Hypertens. 2022; 28(1):14.

PMID: 35568958 PMC: 9107678. DOI: 10.1186/s40885-022-00197-3.

New Series of VEGFR-2 Inhibitors and Apoptosis Enhancers: Design, Synthesis and Biological Evaluation.

Abdallah A, Mabrouk R, Elnagar M, Farrag A, Kalaba M, Sharaf M Drug Des Devel Ther. 2022; 16:587-606.

PMID: 35281317 PMC: 8904266. DOI: 10.2147/DDDT.S344750.

References

Shirasaki Y, Tsushima T, Nasu Y, Kumon H . Long-term consequence of renal function following nephrectomy for renal cell cancer. Int J Urol. 2004; 11(9):704-8. DOI: 10.1111/j.1442-2042.2004.00879.x. View

George S, Wang Q, Heinrich M, Corless C, Zhu M, Butrynski J . Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol. 2012; 30(19):2401-7. PMC: 3675695. DOI: 10.1200/JCO.2011.39.9394. View

Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M . Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2012; 381(9863):303-12. DOI: 10.1016/S0140-6736(12)61900-X. View

Rini B, Cohen D, Lu D, Chen I, Hariharan S, Gore M . Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2011; 103(9):763-73. PMC: 3086879. DOI: 10.1093/jnci/djr128. View

Davis S, Eckhardt S, Messersmith W, Jimeno A . The development of regorafenib and its current and potential future role in cancer therapy. Drugs Today (Barc). 2013; 49(2):105-15. DOI: 10.1358/dot.2013.49.2.1930525. View

Melman A, Grim C, Weinberger M . Increased incidence of renal cell carcinoma with hypertension. J Urol. 1977; 118(4):531-2. DOI: 10.1016/s0022-5347(17)58097-0. View

Banfor P, Franklin P, Segreti J, Widomski D, Davidsen S, Albert D . ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats. J Cardiovasc Pharmacol. 2009; 53(2):173-8. DOI: 10.1097/FJC.0b013e3181993493. View

Belum V, Wu S, Lacouture M . Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. Invest New Drugs. 2013; 31(4):1078-86. DOI: 10.1007/s10637-013-9977-0. View

Aronow W . Optimal Blood Pressure Goals in Patients With Hypertension at High Risk for Cardiovascular Events. Am J Ther. 2013; 23(1):e218-23. DOI: 10.1097/MJT.0b013e31827c5372. View

10.

Eisen T, Joensuu H, Nathan P, Harper P, Wojtukiewicz M, Nicholson S . Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncol. 2012; 13(10):1055-62. DOI: 10.1016/S1470-2045(12)70364-9. View

11.

Strumberg D, Schultheis B . Regorafenib for cancer. Expert Opin Investig Drugs. 2012; 21(6):879-89. DOI: 10.1517/13543784.2012.684752. View

12.

Qi W, He A, Shen Z, Yao Y . Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis. Br J Clin Pharmacol. 2013; 76(3):348-57. PMC: 3769663. DOI: 10.1111/bcp.12149. View

13.

Kappers M, de Beer V, Zhou Z, Danser A, Sleijfer S, Duncker D . Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension. 2011; 59(1):151-7. DOI: 10.1161/HYPERTENSIONAHA.111.182220. View

14.

Izzedine H, Ederhy S, Goldwasser F, Soria J, Milano G, Cohen A . Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol. 2009; 20(5):807-15. DOI: 10.1093/annonc/mdn713. View

15.

Wilhelm S, Dumas J, Adnane L, Lynch M, Carter C, Schutz G . Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2010; 129(1):245-55. DOI: 10.1002/ijc.25864. View

16.

Motzer R, Hutson T, Tomczak P, Michaelson M, Bukowski R, Rixe O . Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356(2):115-24. DOI: 10.1056/NEJMoa065044. View

17.

Demetri G, Reichardt P, Kang Y, Blay J, Rutkowski P, Gelderblom H . Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2012; 381(9863):295-302. PMC: 3819942. DOI: 10.1016/S0140-6736(12)61857-1. View

18.

Chu T, Rupnick M, Kerkela R, Dallabrida S, Zurakowski D, Nguyen L . Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007; 370(9604):2011-9. PMC: 2643085. DOI: 10.1016/S0140-6736(07)61865-0. View

19.

Kappers M, Smedts F, Horn T, van Esch J, Sleijfer S, Leijten F . The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system. Hypertension. 2011; 58(2):295-302. DOI: 10.1161/HYPERTENSIONAHA.111.173559. View

20.

Qi W, Shen Z, Lin F, Sun Y, Min D, Tang L . Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials. Br J Clin Pharmacol. 2012; 75(4):919-30. PMC: 3612709. DOI: 10.1111/j.1365-2125.2012.04417.x. View